Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects to report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback